Journey Medical Corporation (NASDAQ:DERM) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET
Company Participants
Claude Maraoui - Co-Founder President and Chief Executive Officer
Ernest De Paolantonio - Chief Financial Officer
Ramsey Alloush - General Counsel
Dr. Srinivas Sidgiddi - Vice President of Clinical Development and Medical Affairs
Jules Abraham - IR, CORE IR
Conference Call Participants
Brandon Folkes - Cantor Fitzgerald
Mayank Mamtani - B. Riley FBR
Operator
Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Journey Medical’s Second Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and it's also being recorded for playback purposes. Our webcast replay of the call will be available approximately one hour after the end of the call for approximately 30 days.
I would like now to turn the call over to Jules Abraham of CORE IR, the Company's Investor Relations. Please go ahead, sir.
Jules Abraham
Thank you, Carolyn. Good afternoon, everyone. And thank you for participating in today's conference call. Joining me from Journey medical Corporation's leadership today are Claude Maraoui, Co-Founder President and Chief Executive Officer, Ernest De Paolantonio, Chief Financial Officer, Ramsey Alloush, General Counsel and Dr. Srinivas Sidgiddi, Vice President of Clinical Development and Medical Affairs, who will also be joining us for the question-and-answer session.
During this call, management will be making forward-looking statements including statements that address Journey Medical's expectations for future performance or operational results. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described Journey Medical's most recently filed periodic reports, on Form 10-K and Form 10-Q, Form 8-K filed with the SEC today, and the company's press release that accompanies this call, particularly the cautionary statements within.
Today's conference call includes non-GAAP financial measures that Journey Medical believes can be useful in evaluating its performance. You should not consider this additional information in isolation, nor as a substitute for results prepared in accordance with GAAP. For reconciliation of this non GAAP financial measure to net loss, its most directly comparable GAAP financial measure, please see the reconciliation table located in the company's earnings press release.